Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2012-03-01 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is a media release announcing the publication of Phase III clinical trial results for the drug INC424 (ruxolitinib) in the New England Journal of Medicine. It discusses clinical trial outcomes, regulatory filing plans, and drug development updates. There are no financial statements, detailed financial analysis, or comprehensive management discussion typical of annual or interim reports. The document is primarily a regulatory announcement and media release about clinical trial results and upcoming regulatory submissions, not a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2012-03-01 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It contains a media release about the European Commission's approval of a new label for a drug, Glivec, including clinical study results and safety information. The document is not an annual report, audit report, earnings release, or any other detailed financial report. It is a regulatory filing providing material information to the SEC and investors about a significant corporate event (drug label approval and clinical study results). The document length is about 15,000 characters, which is substantial but the content is primarily a press release and regulatory disclosure rather than a financial report or presentation. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and disclosures that do not fit other specific categories.
2012-02-28 English
4
Director's Dealing
2012-02-23 English
6-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content includes a media release about the Annual General Meeting (AGM) results, including shareholder approvals of dividend increases, election and re-election of board members, and reaffirmation of company outlook. It also contains forward-looking statements and company background information. The document is not the full annual report or financial statements but rather an announcement of AGM outcomes and related shareholder resolutions. The length is about 13,111 characters, which is consistent with a detailed announcement but not a full report like a 10-K or 20-F. Therefore, the document fits best into the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports on shareholder voting results at the AGM, including dividend approval and board elections.
2012-02-23 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of a media release about regulatory updates concerning the drug Rasilez, including product information revisions requested by the European Medicines Agency's CHMP. It includes detailed information about the regulatory review, safety concerns, and company responses. There are no financial statements or detailed financial performance data presented, nor is this an earnings release or annual/interim report. The document is not a proxy, voting result, or management change announcement. It is a regulatory update and communication to the market about product safety and regulatory decisions. Given the nature of the filing (Form 6-K) and the content, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories. The document length is over 13,000 characters, indicating it is a full filing, not just a brief announcement of a report publication.
2012-02-17 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is a media release about the FDA requesting additional data on a vaccine, Menveo, for expanded use in infants and toddlers. It includes detailed information about the vaccine, safety information, and company background. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The document is a regulatory announcement providing information to the SEC and the public about a regulatory development related to the company's product. It is not an earnings release, annual report, or any other financial report type. It is also not a report publication announcement since it contains substantive information rather than just announcing a report's availability. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2012-02-13 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.